ENANTIS SRO

Their core work

Enantis is a Czech biotech SME specializing in protein engineering and stabilization, with a core product line around industrially stable Fibroblast Growth Factors (FGFs) for regenerative medicine and research applications. They progressed through the EU SME Instrument from feasibility (Phase 1) to full commercialization (Phase 2), indicating a company moving from R&D into market-ready production. Beyond their flagship FGF work, they contribute protein engineering and directed evolution expertise to synthetic biology consortia focused on optimizing industrial bioprocesses and biocatalysis.

What they specialise in

How they've shifted over time

Enantis entered H2020 in 2015 with a focused commercial mission: stabilizing Fibroblast Growth Factors for industrial production (FGFSTAB Phase 1). By 2017, they expanded into broader synthetic biology and protein evolution consortia (Rafts4Biotech, ES-Cat) while simultaneously scaling their core FGF product through SME Instrument Phase 2. The trajectory shows a company that anchored itself in a niche product, then deliberately broadened its scientific network and methodological toolkit — likely to strengthen the protein engineering platform underlying their commercial offering.

Enantis is building toward becoming a full-service protein engineering SME, combining their proprietary stabilization technology with directed evolution and bioprocess optimization capabilities gained through collaborative research.

How they like to work

Enantis balances leadership and partnership equally — they coordinated their own product-focused projects (FGFSTAB) while joining larger research consortia (Rafts4Biotech, ES-Cat) as a specialist contributor. With 27 unique partners across 12 countries from just 4 projects, they are well-connected for their size. This pattern suggests they are confident enough to drive their own agenda but pragmatic enough to embed themselves in academic networks where they can access frontier science.

Despite being a small biotech SME, Enantis has built a notably broad network of 27 partners across 12 countries through just 4 projects. Their participation in a Marie Curie training network (ES-Cat) and a multi-partner RIA (Rafts4Biotech) gives them strong academic connections across Europe.

What sets them apart

Enantis occupies a rare niche as a Czech SME that bridges computational protein design with industrial biologics production. Their successful progression from SME Instrument Phase 1 to Phase 2 — a path only about 10% of applicants complete — demonstrates both scientific credibility and commercial viability. For consortium builders, they offer hands-on protein stabilization expertise with a proven track record of translating research into products, which is exactly the kind of partner evaluators want to see in exploitation-focused proposals.

Highlights from their portfolio

• FGFSTAB
  Rare example of an SME completing the full Phase 1 → Phase 2 SME Instrument journey, securing EUR 1.08M total to bring stabilized growth factors from feasibility to industrial production.
• ES-Cat
  Marie Curie training network on directed protein evolution — unusual for an SME to participate, indicating strong academic recognition of their expertise.
• Rafts4Biotech
  Multi-partner synthetic biology project connecting Enantis to the broader European bioprocess optimization community through work on lipid raft engineering.